Brief: Senti Bio Reports Q2 Results
15/08/2022 21:07
Aug 15 (Reuters) - Senti Biosciences Inc SNTI.O :
* SENTI BIO REPORTS SECOND QUARTER FINANCIAL RESULTS AND
BUSINESS
UPDATES
* SENTI BIOSCIENCES INC - CASH POSITION OF $139.8 MILLION AS
OF
JUNE 30, 2022 EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2024
* SENTI BIOSCIENCES INC - QTRLY LOSS PER SHARE $0.86
Source text for Eikon: ID:nGNX6H6CZh
Further company coverage: SNTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates